1. Health Physics Consequences of Out-Patient Treatment of Non-Hodgkinʼs Lymphoma with 131I-radiolabeled Anti-B1 Antibody
- Author
-
Hargrove H, Michael T. Ryan, Bloodworth G, Ehsan Samei, Frey Gd, Spicer Km, and Frei-Lahr D
- Subjects
Adult ,Male ,medicine.medical_specialty ,Epidemiology ,Health, Toxicology and Mutagenesis ,medicine.medical_treatment ,Iodine Radioisotopes ,Healthcare delivery ,Outpatients ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Patient treatment ,Aged ,biology ,business.industry ,Lymphoma, Non-Hodgkin ,Risk of infection ,Radiotherapy Dosage ,Middle Aged ,Radioimmunotherapy ,medicine.disease ,Surgery ,Lymphoma ,Non-Hodgkin's lymphoma ,Radiation therapy ,Clinical trial ,Emergency medicine ,biology.protein ,Female ,Antibody ,business ,Health Physics - Abstract
The Medical University of South Carolina is currently participating in clinical trials of 131I radiolabeled Anti-B1 antibody for treatment of Non-Hodgkin's lymphoma. Under current South Carolina Department of Health and Environmental Control regulatory guidelines,; these patients are required to be admitted to the hospital and to remain as inpatients until the whole body burden is
- Published
- 2000
- Full Text
- View/download PDF